Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

Cited by (684)

Items 101–200 of 684

1. TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target
   Jiaojiao Yu, Dandan Zhou, Xiaoxiao Yang, Bing Cui, Fengwei Tan, Junjian Wang, Ke Li, Shuang Shang, Cheng Zhang, Xiaoxi Lv et al. · 2020 · Nature Communications
2. Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
   Rong Wang, Tadaaki Yamada, Kenji Kita, Hirokazu Taniguchi, Sachiko Arai, Koji Fukuda, Minoru Terashima, Akihiko Ishimura, Akihiro Nishiyama, Azusa Tanimoto et al. · 2020 · Nature Communications
3. Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations
   David König, Spasenija Savic Prince, Sacha I. Rothschild · 2021 · Cancers
4. Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach
   Julian Engel, André Richters, Matthäus Getlik, Stefano Tomassi, Marina Keul, Martin Termathe, Jonas Lategahn, Christian Becker, Svenja C. Mayer‐Wrangowski, Christian Grütter et al. · 2015 · Journal of Medicinal Chemistry
5. Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line
   Ivana Sullivan, David Planchard · 2017 · Frontiers in Medicine
6. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer
   Jing Gao, Hao-Ran Li, C. Jin, Jingwei Jiang, Jian‐Yong Ding · 2019 · Clinical & Translational Oncology
7. Recent progress on third generation covalent EGFR inhibitors
   Hengmiao Cheng, Sajiv K. Nair, Brion William Murray · 2016 · Bioorganic & Medicinal Chemistry Letters
8. Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going
   Alessandro Russo, Tindara Franchina, Giuseppina Rosaria Rita Ricciardi, Valeria Smiroldo, M. Picciotto, Mariangela Zanghì, Christian Diego Rolfo, Vincenzo Adamo · 2017 · Critical Reviews in Oncology/Hematology
9. Targeting EGFR in Lung Cancer: Current Standards and Developments
   Díaz-Serrano, Asunción, Gella, Pablo, Jiménez, Elisabeth, Zugazagoitia, Jon, Paz-Ares Rodríguez, Luis · 2018 · Drugs
10. Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer
    Zhendong Song, Ge Yang, Changyuan Wang, Shanshan Huang, Xiaohong H. Shu, Kexin Liu, Youwen Zhou, Xiaodong Ma · 2016 · Journal of Medicinal Chemistry
11. Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer
    Hui Pan, Tao Jiang, Ningning Cheng, Qi Wang, Shengxiang Ren, Xuefei Li, Chao Zhao, Limin Zhang, Weijing Cai, Caicun Zhou · 2016 · Oncotarget
12. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer
    Tan, Chee-Seng, Cho, Byoung-Chul, Soo, Ross A. · 2016 · Lung Cancer
13. Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes
    Zheng Yang, Kin Yip Tam · 2018 · International Journal of Biological Sciences
14. Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy‐Resistant L858R/T790M/C797S Mutant
    Marcel Günther, Michael Juchum, Gerhard Kelter, Heiner H. Fiebig, Stefan Laufer · 2016 · Angewandte Chemie International Edition
15. The next tier of EGFR resistance mutations in lung cancer
    Hannah Lea Tumbrink, Alena Heimsoeth, Martin L. Sos · 2020 · Oncogene
16. Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary
    Nasser H. Hanna, David H. Johnson, Sarah Temin, Gregory A. Masters · 2017 · Journal of Oncology Practice
17. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
    Mariacarmela Santarpía, Alessia Liguori, Niki Karachaliou, María González‐Cao, Maria Grazia Daffinà, Alessandro D’Aveni, Grazia Marabello, Giuseppe Altavilla, Rafael Rosell · 2017 · Lung Cancer Targets and Therapy
18. EGFR as a Pharmacological Target in EGFR -Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?
    Erjing Ke, Yi-Long Lung Cancer Wu · 2016 · Trends in Pharmacological Sciences
19. Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology
    Rashmi R. Shah, Devron R. Shah · 2019 · Drug Safety
20. Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer
    Houssein Chhouri, David Alexandre, Luca Grumolato · 2023 · Cancers
21. Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature
    Anthonie J. van der Wekken, Ali Saber, T. Jeroen N. Hiltermann, Klaas Kok, A. van den -->Berg, Harry J.M. Groen · 2016 · Critical Reviews in Oncology/Hematology
22. Acute kidney injury subphenotypes based on creatinine trajectory identifies patients at increased risk of death
    Pavan K. Bhatraju, Paramita Mukherjee, Cassianne Robinson‐Cohen, Grant Edward O’Keefe, Angela J. Frank, Jason D. Christie, Nuala J. Meyer, Kathleen D. Liu, Michael A. Matthay, Carolyn S. Calfee et al. · 2016 · Critical Care
23. Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors
    Leilei Wu, Linping Ke, Zhenshan Zhang, Jinming Yu, Xue Meng · 2020 · Frontiers in Oncology
24. Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors
    Shuhang Wang, Yongping Song, Feifei Yan, Delong Liu · 2016 · Frontiers of Medicine
25. Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients
    Norikazu Matsuo, Koichi Azuma, Kazuko Sakai, Satoshi Hattori, Akihiko Kawahara, Hidenobu Ishii, Takaaki Tokito, Takashi Kinoshita, Kazuhiko Yamada, Kazuto Nishio et al. · 2016 · Scientific Reports
26. Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1 H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers
    Lelais, Gérald, Epple, Robert, Marsilje, Thomas H., Long, Yun O., McNeill, Matthew, Chen, Bei, Lu, Wenshuo, Anumolu, Jaganmohan, Badiger, Sangamesh, Bursulaya, Badry et al. · 2016 · Journal of Medicinal Chemistry
27. Platelets, circulating tumor cells, and the circulome
    Preeti Kanikarla Marie, Michael S. Lam, David G. Menter, Scott Kopetz · 2017 · Cancer and Metastasis Reviews
28. Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes
    Hengyi Chen, Wenxiu Yao, Qian Chu, Rui Han, Yubo Wang, Jianguo Sun, Dong Wang, Yongsheng Wang, Mengshu Cao, Yong He · 2015 · Cancer Letters
29. Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
    Natalie Andrews Wright, Glenwood D. Goss · 2019 · Translational Lung Cancer Research
30. First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations
    Yusuke Okuma, Kaoru Kubota, Mototsugu Shimokawa, Kana Hashimoto, Yosuke Kawashima, Tomohiro Sakamoto, Hiroshi Wakui, Shuji Murakami, Kyoichi Okishio, Kenji Hayashihara et al. · 2023 · JAMA Oncology
31. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations
    Arena, Sabrina, Siravegna, Giulia, Mussolin, Benedetta, Kearns, Jeffrey D., Wolf, Beni B., Misale, Sandra, Lazzari, Luca, Bertotti, Andrea, Trusolino, Livio, Adjei, Alex A. et al. · 2016 · Science Translational Medicine
32. Addressing intra-tumoral heterogeneity and therapy resistance
    Brad Rybinski, Kyuson Yun · 2016 · Oncotarget
33. Emerging therapeutic agents for lung cancer
    Bhagirathbhai Dholaria, William A. Hammond, Amanda J. Shreders, Yanyan Lou · 2016 · Journal of Hematology & Oncology
34. New Benzimidazole-, 1,2,4-Triazole-, and 1,3,5-Triazine-Based Derivatives as Potential EGFR WT and EGFR T790M Inhibitors: Microwave-Assisted Synthesis, Anticancer Evaluation, and Molecular Docking Study
    Heba E. Hashem, Abd El‐Galil E. Amr, Eman Samir Nossier, Manal M. Anwar, Eman M. Azmy · 2022 · ACS Omega
35. Can EGFR be a therapeutic target in breast cancer?
    Xi‐Yin Li, Lina Zhao, Ceshi Chen, Jianyun Nie, Baowei Jiao · 2022 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
36. Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer
    Julian Engel, Jonas Lategahn, Daniel Rauh · 2015 · ACS Medicinal Chemistry Letters
37. NCI-60 Cell Line Screening: A Radical Departure in its Time
    Bruce Allan Chabner · 2016 · JNCI Journal of the National Cancer Institute
38. Drug Resistance to EGFR Inhibitors in Lung Cancer
    Osamu Tetsu, Matthew J. Hangauer, Janyaporn Phuchareon, David W. Eisele, Frank P. McCormick · 2016 · Chemotherapy
39. Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR- Mutant Lung Cancer
    Azusa Tanimoto, Shinji Takeuchi, Sachiko Arai, Koji Fukuda, Tadaaki Yamada, Xavier Roca, S. Tiong Ong, Seiji Yano · 2016 · Clinical Cancer Research
40. AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients
    Xu, Xiao, Mao, Long, Xu, Wanhong, Tang, Wei, Zhang, Xiaoying, Xi, Biao, Xu, Rongda, Fang, Xin, Liu, Jia, Fang, Ce et al. · 2016 · Molecular Cancer Therapeutics
41. Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
    Banno, Eri, Togashi, Yosuke, Nakamura, Yu, Chiba, Masato, Kobayashi, Yoshihisa, Hayashi, Hidetoshi, Terashima, Masato, de Velasco, Marco A., Sakai, Kazuko, Fujita, Yoshihiko et al. · 2016 · Cancer Science
42. Rebiopsy for patients with non‐small‐cell lung cancer after epidermal growth factor receptor‐tyrosine kinase inhibitor failure
    Takahisa Kawamura, Hirotsugu Kenmotsu, Tetsuhiko Taira, Shota Omori, Kazuhisa Nakashima, Kazushige Wakuda, Akira Ono, Tateaki Naito, Haruyasu Murakami, Keita P. Mori et al. · 2016 · Cancer Science
43. Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer
    Kenichi Suda, Isao Murakami, Kazuko Sakai, Hiroshi Mizuuchi, Shigeki Shimizu, Katsuaki Sato, Kenji Tomizawa, Shuta Tomida, Yasushi Yatabe, Kazuto Nishio et al. · 2015 · Scientific Reports
44. Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer
    William Kelly, Neil J. Shah, Deepa Suresh Subramaniam · 2018 · Frontiers in Oncology
45. Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Who Previously Progressed on Erlotinib
    Primo N. Lara, Jeff Longmate, Philip C. Mack, Karen L. Kelly, Mark A. Socinski, Ravi Salgia, Barbara Jennifer Gitlitz, Tianhong Li, Mariana Koczywas, Karen L. Reckamp et al. · 2015 · Clinical Cancer Research
46. Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA
    Marzia Del Re, Marcello Tiseo, Paola Bordi, Armida D’Incecco, Andrea Camerini, Iacopo Petrini, M Lucchesi, Alessandro Inno, Daniele Spada, Enrico Vasile et al. · 2016 · Oncotarget
47. Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management
    Jonathan Wade Goldman, Melody A. Mendenhall, Sarah R. Rettinger · 2016 · The Oncologist
48. Dynamics of multiple resistance mechanisms in plasma DNA during EGFR‐targeted therapies in non‐small cell lung cancer
    Dana W.Y. Tsui, Muhammed Murtaza, Alvin Seng Cheong Wong, Oscar M. Rueda, Christopher G. Smith, Dineika Chandrananda, Ross Andrew Soo, Hong Liang Lim, Boon Cher Goh, Carlos Caldas et al. · 2018 · EMBO Molecular Medicine
49. Brain Metastases from NSCLC: Radiation Therapy in the Era of Targeted Therapies
    Jonathan Khalifa, Arya Amini, Sanjay Popat, Laurie E. Gaspar, Corinne Faivre Finn · 2016 · Journal of Thoracic Oncology
50. Role of circulating-tumor DNA analysis in non-small cell lung cancer
    Tao Jiang, Shengxiang Ren, Caicun Zhou · 2015 · Lung Cancer
51. Integrating cancer genomic data into electronic health records
    Jeremy Lyle Warner, Sandeep Kumar Jain, Mia Alyce Levy · 2016 · Genome Medicine
52. Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045
    Peng Zhao, Ming-Yu Yao, Sujie Zhu, Jiyun Chen, Cai‐Hong Yun · 2018 · Biochemical and Biophysical Research Communications
53. Liquid Biopsy in Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society
    Lynette Marie Sholl, Dara L. Aisner, Timothy Craig Allen, Mary Beth Beasley, Philip T. Cagle, Vera Luíza Capelozzi, Sanja Đačić, Lida P. Hariri, Keith M. Kerr, Sylvie Lantuéjoul et al. · 2016 · Archives of Pathology & Laboratory Medicine
54. Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer
    Yoshihisa Kobayashi, Koichi Azuma, Hiroki Nagai, Young Hak Kim, Yosuke Togashi, Yuichi Sesumi, Masato Chiba, Masaki Shimoji, Katsuaki Sato, Kenji Tomizawa et al. · 2016 · Molecular Cancer Therapeutics
55. Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer
    Olivier Bylicki, Nicolas Paleiron, J. Margery, Florian Guisier, Alain Vergnenégre, G. Robinet, J.B. Auliac, R. Gervais, CHRISTOS CHOUAID · 2017 · Targeted Oncology
56. Expression of Neuroendocrine Factor VGF in Lung Cancer Cells Confers Resistance to EGFR Kinase Inhibitors and Triggers Epithelial-to-Mesenchymal Transition
    Wen Hwang, Yu-Fan Chiu, Ming-Han Kuo, Kuan-Lin Lee, An-Chun Lee, Chia-Cherng Yu, Junn-Liang Chang, Wen-Chien Huang, Shih-Hsin Hsiao, Sey‐En Lin et al. · 2017 · Cancer Research
57. Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine
    Izhar Singh Batth, Abhisek Mitra, Salomon Manier, Irene M. Ghobrial, David G. Menter, Scott Kopetz, Songyun Li · 2016 · Annals of Oncology
58. Cell-Free DNA: Applications in Different Diseases
    Rossella Ranucci · 2018 · Methods in molecular biology
59. Update to Rociletinib Data with the RECIST Confirmed Response Rate
    Lecia Van Dam Sequist, Jean‐Charles Soria, D. Ross Camidge · 2016 · New England Journal of Medicine
60. Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer
    Yonggang Meng, Bin Yu, He Huang, Youmei Peng, Ertong Li, Yongfang Yao, Chuanjun Song, Wenquan Yu, Kaikai Zhu, Kai Wang et al. · 2021 · Journal of Medicinal Chemistry
61. Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR- Mutant Non–Small Cell Lung Cancer
    York, Emily R., Varella-Garcia, Marileila, Bang, Tami J., Aisner, Dara L., Camidge, D. Ross · 2017 · Journal of Thoracic Oncology
62. Enhanced Glycolysis Supports Cell Survival in EGFR-Mutant Lung Adenocarcinoma by Inhibiting Autophagy-Mediated EGFR Degradation
    Ji Hye Kim, Boas Nam, Yun Jung Choi, Seon Ye Kim, Jungeun Lee, Ki Jung Sung, Woo Sung Kim, Chang‐Min Choi, Eun‐Ju Chang, Jae Soo Koh et al. · 2018 · Cancer Research
63. Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study
    Daniel S.W. Tan, Natasha B. Leighl, Gregory J. Riely, James Chih‐Hsin Yang, Lecia Van Dam Sequist, Juergen Wolf, Takashi Seto, Enriqueta Felip, Santiago Ponce-Aix, Maud Jonnaert et al. · 2020 · The Lancet Respiratory Medicine
64. Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer
    Viola Weijia Zhu, Samuel Jacob Klempner, Sai‐Hong Ignatius Ou · 2019 · Trends in cancer
65. Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment
    Antonio Passaro, Elena Guerini‐Rocco, Alessia Pochesci, Davide Vacirca, Gianluca Spitaleri, Chiara Catania, Alessandra Rappa, Massimo C.P. Barberis, Filippo de Marinis · 2017 · Pharmacological Research
66. Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study)
    Takayuki Takahama, Kazuko Sakai, Masayuki Takeda, Koichi Azuma, Toyoaki Hida, Masataka Hirabayashi, Tetsuya Oguri, Hiroshi Tanaka, Noriyuki Ebi, Toshiyuki Sawa et al. · 2016 · Oncotarget
67. Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent Resistance
    Xu Zhang, Tapan Kumar Maity, Karen E. ROSS, Yue Andy Qi, Constance M. Cultraro, Meriam Bahta, Stephanie C. Pitts, Meghana Keswani, Shaojian Gao, Khoa Dang P. Nguyen et al. · 2021 · Cancer Research
68. MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells
    Kristine Raaby Jakobsen, Christina Demuth, Anne Tranberg Madsen, Dianna Hussmann, Johan Vad‐Nielsen, Anders Lade Nielsen, Boe Sandahl Sørensen · 2017 · Oncogenesis
69. Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors
    Rita Dorantes-Heredia, José Manuel Ruiz-Morales, Fernando Cano-García · 2016 · Translational Lung Cancer Research
70. Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery
    Kenneth K. Hallenbeck, David Turner, Adam R. Renslo, Michelle R. Arkin · 2016 · Current Topics in Medicinal Chemistry
71. The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic
    Katerina A. Politi, Deborah O. Ayeni, Thomas James Lynch · 2015 · Cancer Cell
72. The potential of liquid biopsies
    Anna Buder, Christian Tomuta, Martin Filipits · 2016 · Current Opinion in Oncology
73. Novel Tumor Suppressor lncRNA Growth Arrest-Specific 5 (GAS5) In Human Cancer
    Yaya Yu, Swei Sunny Hann · 2019 · OncoTargets and Therapy
74. Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer.
    Paola Bordi, Marzia Del Re, Romano Danesi, Marcello Tiseo · 2015 · PubMed Central
75. A systematic review of targeted agents for non-small cell lung cancer
    Hannah Holm Vestergaard, Marcus R. Christensen, Ulrik Lassen · 2017 · Acta Oncologica
76. Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR -Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target
    Kyung-A Song, Yasuyuki Hosono, Crystal Turner, Sheeba Jacob, Timothy L. Lochmann, Yoshiko Murakami, Neha U. Patel, Jungoh Ham, Bin Hu, Krista M. Powell et al. · 2018 · Clinical Cancer Research
77. Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer
    Michihiko Kuwano, Kahori Sonoda, Yûichi Murakami, Kosuke Watari, Mayumi Ono · 2016 · Pharmacology & Therapeutics
78. Epidermal growth factor receptor inhibitors as potential anticancer agents: An update of recent progress
    Bharti Sharma, Vikram Jeet Singh, Pooja A. Chawla · 2021 · Bioorganic Chemistry
79. Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience
    Ivana Sullivan, David Planchard · 2016 · Therapeutic Advances in Respiratory Disease
80. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
    Kimio Yonesaka, Keita Kudo, Satomi Nishida, Takayuki Takahama, Tsutomu Iwasa, Takeshi Yoshida, Kaoru Tanaka, Masayuki Takeda, Hiroyasu Kaneda, Isamu Okamoto et al. · 2015 · Oncotarget
81. Insight into the Inhibition of Drug‐Resistant Mutants of the Receptor Tyrosine Kinase EGFR
    Julian Engel, Christian Becker, Jonas Lategahn, Marina Keul, Julia Ketzer, Thomas Mühlenberg, Laxmikanth Kollipara, Carsten Schultz‐Fademrecht, René Peiman Zahedi, Sebastian Bauer et al. · 2016 · Angewandte Chemie International Edition
82. Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer
    Haijun Zhang · 2016 · Drug Design Development and Therapy
83. Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor
    Elena Helman, Minh Nguyen, Chris Karlovich, Darrin Despain, A. Karin Choquette, Alexander I. Spira, Helena Alexandra Yu, D. Ross Camidge, Thomas C. Harding, Richard Burnham Lanman et al. · 2018 · Clinical Lung Cancer
84. Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer
    Meghan J. Campo, H. Al-Halabi, Melin Janardan Khandekar, Alice Tsang Shaw, Lecia Van Dam Sequist, Henning Willers · 2016 · The Oncologist
85. Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
    2015 · New England Journal of Medicine
86. Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
    Tristan Alexandra Barnes, Grainne Mary O'Kane, Mark David Vincent, Natasha B. Leighl · 2017 · Frontiers in Oncology
87. A sulfonyl fluoride derivative inhibits EGFRL858R/T790M/C797S by covalent modification of the catalytic lysine
    Francesca Ferlenghi, Laura Scalvini, Federica Vacondio, Riccardo Castelli, Nicole Bozza, Giuseppe Marseglia, Silvia Rivara, Alessio Lodola, Silvia La Monica, Roberta Minari et al. · 2021 · European Journal of Medicinal Chemistry
88. The functions and molecular mechanisms of Tribbles homolog 3 (TRIB3) implicated in the pathophysiology of cancer
    Anam Arif, Ameer A. Alameri, Umer Bin Tariq, Shakeel Ahmed Ansari, Hader I. Sakr, Maytham Talib Qasim, Fadhil Farhood M. Al-joborae, Andrés Alexis Ramírez‐Coronel, Hijran Sanaan Jabbar, Gamal A. Gabr et al. · 2022 · International Immunopharmacology
89. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition
    Wei Lou, Yan Chen, Keying Zhu, Huizi Deng, Tianhao Wu, Jun Wang · 2017 · Biological and Pharmaceutical Bulletin
90. Addressing the challenges of applying precision oncology
    Seung Ho Shin, Ann M. Bode, Zigang Dong · 2017 · npj Precision Oncology
91. Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC
    Anna Buder, Maximilian Johannes Hochmair, Sophia Schwab, Tatjana Bundalo, Peter Schenk, Peter Errhalt, Romana E. Mikes, Gudrun Absenger, Kurt Patocka, Bernhard Baumgartner et al. · 2018 · Journal of Thoracic Oncology
92. Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib
    Lecia Van Dam Sequist, Zofia Piotrowska, Matthew J. Niederst, Rebecca Suk Heist, Subba Rao Digumarthy, Alice Tsang Shaw, Jeffrey A. Engelman · 2015 · JAMA Oncology
93. Design, synthesis, and biological evaluation of novel quinoline derivatives as small molecule mutant EGFR inhibitors targeting resistance in NSCLC: In vitro screening and ADME predictions
    Ramakant Asaram Kardile, Aniket P. Sarkate, Deepak K. Lokwani, Shailee V. Tiwari, Rajaram Azad, Shankar R. Thopate · 2022 · European Journal of Medicinal Chemistry
94. Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics
    S.W. Ember, Que T. Lambert, Norbert Berndt, Steven Gunawan, Muhammad Ayaz, Marilena Tauro, Jin‐Yi Zhu, Paula J. Cranfill, Patricia Greninger, Conor C. Lynch et al. · 2017 · Molecular Cancer Therapeutics
95. High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells
    Shigeki Nanjo, Hiromichi Ebi, Sachiko Arai, Shinji Takeuchi, Tadaaki Yamada, Satsuki Mochizuki, Yasunori Okada, Mitsutoshi Nakada, Takashi Murakami, Seiji Yano · 2015 · Oncotarget
96. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials
    S.S. Ramalingam, Kenneth John O'Byrne, Michael Joseph Boyer, Tony S.K. Mok, Pasi Antero Janne, Hui Zhang, Jonathan J. Liang, Ian W. Taylor, Eric I. Sbar, Luiz Paz-Ares · 2016 · Annals of Oncology
97. Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers
    Helena Alexandra Yu, Cami S. Sima, Darren Richard Feldman, Lantian Liu, Bhavapriya Vaitheesvaran, Jason B. Cross, Charles M. Rudin, Mark G. Kris, William J. Pao, Franziska Michor et al. · 2016 · Annals of Oncology
98. Liquid biopsy genotyping in lung cancer: ready for clinical utility?
    Wei-Lun Huang, Yi-Lin Chen, Szu‐Chun Yang, Chung‐Liang Ho, Fang Wei, David T. Wong, Wu‐Chou Su, Chien‐Chung Lin · 2017 · Oncotarget
99. Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer
    Saoirse Olivia Dolly, Dearbhaile Catherine Collins, Raghav Sundar, Sanjay Popat, Timothy A. Yap · 2017 · Drugs
100. Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3
     Nadège Gaborit, Moshit Lindzen, Yosef Yarden · 2015 · Human Vaccines & Immunotherapeutics